Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Anti-EGFR Monoclonal Antibody Mixture Sym004

Known as: Futuximab/Zatuximab, Sym004 
A mixture of two recombinant IgG1 antibodies directed against different epitopes in the epidermal growth factor receptor (EGFR) extracellular domain… Expand
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized…
Importance Acquired resistance to anti-EGFR therapy (epidermal growth factor receptor) is frequently due to RAS and EGFR… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Review
2017
Review
2017
EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise
The receptor for epidermal growth factor (EGFR) is a prime target for cancer therapy across a broad variety of tumor types. As it… Expand
  • figure 1
  • table 1
  • table 2
2016
2016
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Purpose: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic… Expand
  • table 1
  • table 2
Highly Cited
2015
Highly Cited
2015
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.
UNLABELLED Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2015
2015
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck
AbstractPurposeThe purpose of the trial was to assess the efficacy and tolerability of Sym004, a novel 1:1 mixture of two… Expand
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2013
Highly Cited
2013
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study.
6002 Background: Sym004 is a first-in-class drug mixture of two mAbs targeting non-overlapping epitopes on the EGFR. In… Expand
Highly Cited
2011
Highly Cited
2011
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor
The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer… Expand
2011
2011
Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor
Purpose: Sym004 is a novel therapeutic antibody mixture product comprising two unmarketed monoclonal antibodies (mAb) targeting… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Highly Cited
2010
Highly Cited
2010
Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
Epidermal growth factor receptor (EGFR) is a validated therapeutic target in cancer and EGFR antagonists with greater… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE